Scholarlink

Introduction <p>Evaluating psoriasis care in Brazil, a country characterized by its vast geographical expanse, may provide valuable lessons for healthcare systems globally. National research has revealed that individuals receiving biologic treatments in Brazil exhibit lower drug survival rates than individuals from other countries, highlighting challenges that may be applicable elsewhere. The aim of this study was to determine whether distribution problems, poor adherence, and improper storage of immunobiological therapeutics are significant risk factors for reduced drug survival during psoriasis treatment.</p> Methods <p>In this retrospective cohort study, patients diagnosed with psoriasis who were receiving immunobiological therapy were enrolled in a real-world registry. Drug distribution, adherence, and storage problems were evaluated as risk factors. The primary endpoint was drug survival. Relative risk (RR) and Kaplan‒Meier analyses were used to assess associations, and multivariable analysis was performed via accelerated failure time modeling.</p> Results <p>Among 166 patients, 82 (49.40%) discontinued treatment. Adalimumab was the most frequently administered biologic (<i>n</i> = 77), followed by secukinumab (<i>n</i> = 40), risankizumab (<i>n</i> = 9), guselkumab (<i>n</i> = 8), infliximab (<i>n</i> = 6), etanercept (<i>n</i> = 4), and ustekinumab (<i>n</i> = 19). Bimekizumab, brodalumab, and certolizumab pegol were each used by one patient. Distribution problems increased the risk of treatment interruption (RR = 1.45, 95% confidence interval [CI]: 1.07–1.95). After adjustment, the adverse impact of distribution problems diminished, most likely because of adalimumab’s more frequent dosing schedule. Adalimumab use was linked to shorter drug survival (hazard ratio = 1.51, 95% CI: 1.01–2.27). Postinjection management also raised concerns: 22.23% of patients reported disposing of biologic waste in the regular trash.</p> Conclusions <p>In settings marked by significant stress within the distribution, storage, and administration chains for immunobiologics, distribution problems appear to negatively affect drug survival. The use of therapies with longer dosing intervals or oral medications may help overcome these barriers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月2日

查看全文
  • Luciana A. Ribeiro,
  • Patrícia S. Kurizky,
  • Rodrigo R. de Sena,
  • Samia Fares,
  • Gabriel B. F. dos Santos,
  • Letícia O. Galvão,
  • Licia Maria H. da Mota,
  • Ciro M. Gomes

摘要

Introduction

Evaluating psoriasis care in Brazil, a country characterized by its vast geographical expanse, may provide valuable lessons for healthcare systems globally. National research has revealed that individuals receiving biologic treatments in Brazil exhibit lower drug survival rates than individuals from other countries, highlighting challenges that may be applicable elsewhere. The aim of this study was to determine whether distribution problems, poor adherence, and improper storage of immunobiological therapeutics are significant risk factors for reduced drug survival during psoriasis treatment.

Methods

In this retrospective cohort study, patients diagnosed with psoriasis who were receiving immunobiological therapy were enrolled in a real-world registry. Drug distribution, adherence, and storage problems were evaluated as risk factors. The primary endpoint was drug survival. Relative risk (RR) and Kaplan‒Meier analyses were used to assess associations, and multivariable analysis was performed via accelerated failure time modeling.

Results

Among 166 patients, 82 (49.40%) discontinued treatment. Adalimumab was the most frequently administered biologic (n = 77), followed by secukinumab (n = 40), risankizumab (n = 9), guselkumab (n = 8), infliximab (n = 6), etanercept (n = 4), and ustekinumab (n = 19). Bimekizumab, brodalumab, and certolizumab pegol were each used by one patient. Distribution problems increased the risk of treatment interruption (RR = 1.45, 95% confidence interval [CI]: 1.07–1.95). After adjustment, the adverse impact of distribution problems diminished, most likely because of adalimumab’s more frequent dosing schedule. Adalimumab use was linked to shorter drug survival (hazard ratio = 1.51, 95% CI: 1.01–2.27). Postinjection management also raised concerns: 22.23% of patients reported disposing of biologic waste in the regular trash.

Conclusions

In settings marked by significant stress within the distribution, storage, and administration chains for immunobiologics, distribution problems appear to negatively affect drug survival. The use of therapies with longer dosing intervals or oral medications may help overcome these barriers.